303 related articles for article (PubMed ID: 6655288)
1. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
2. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
3. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
4. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
Bancroft WH; Scott RM; Eckels KH; Hoke CH; Simms TE; Jesrani KD; Summers PL; Dubois DR; Tsoulos D; Russell PK
J Infect Dis; 1984 Jun; 149(6):1005-10. PubMed ID: 6376649
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
6. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
7. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.
Bancroft WH; Top FH; Eckels KH; Anderson JH; McCown JM; Russell PK
Infect Immun; 1981 Feb; 31(2):698-703. PubMed ID: 7216469
[TBL] [Abstract][Full Text] [Related]
8. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
[TBL] [Abstract][Full Text] [Related]
9. Atypical antibody responses in dengue vaccine recipients.
Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
[TBL] [Abstract][Full Text] [Related]
10. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
[TBL] [Abstract][Full Text] [Related]
11. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
[TBL] [Abstract][Full Text] [Related]
12. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.
Eckels KH; Scott RM; Bancroft WH; Brown J; Dubois DR; Summers PL; Russell PK; Halstead SB
Am J Trop Med Hyg; 1984 Jul; 33(4):684-9. PubMed ID: 6476216
[TBL] [Abstract][Full Text] [Related]
13. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
[TBL] [Abstract][Full Text] [Related]
15. Sequential immunization procedure against Group B arboviruses using living attenuated 17D yellow fever virus, living attenuated Langat E5 virus, and living attenuated dengue 2 virus (New Guinea C isolate).
Price WH; Casals J; Thind I; O'Leary W
Am J Trop Med Hyg; 1973 Jul; 22(4):509-23. PubMed ID: 4352231
[No Abstract] [Full Text] [Related]
16. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
17. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
20. TWO EPISODES OF DENGUE FEVER, CAUSED BY TYPES 4 AND 1 VIRUSES, IN AN INDIVIDUAL PREVIOUSLY IMMUNIZED AGAINST YELLOW FEVER.
CAREY DE; MYERS RM; RODRIGUES FM
Am J Trop Med Hyg; 1965 May; 14():448-50. PubMed ID: 14292751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
